Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China and Boston, USA.

Our current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging our industry-leading core strength in CARD (Computer Accelerated Rational Discovery)...

+Read More+

News & Events

View All
  • 28 Dec, 2021

    Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

    +Read More+
  • 10 Dec, 2021

    Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

    +Read More+
  • 18 Feb, 2021

    Regor Therapeutics Announces Completion of $90 Million Series B Financing

    +Read More+

Core Technologies

CARD, Computer Accelerated Rational Discovery, is a powerful and proprietary technology platform

+ Read more +


Initiated over 15 discovery projects since the inception of Regor

+ Read more +

Career Opportunities

View All

Accelerated Discovery. Breakthrough Medicines.

To serve patients around the world through innovative and clinically differentiated drugs

To accelerate portfolio delivery and value creation through enabling technology platforms

245 Main Street, Second Floor, Cambridge, MA 02142, USA
1206 Zhangjiang Rd, Building C, Pudong New District, Shanghai 201210, China